Literature DB >> 18666325

Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients.

Eugeniy-P Smorodin1, Oleg-A Kurtenkov, Boris-L Sergeyev, Kristel-E Kodar, Valentin-I Chuzmarov, Vladimir-P Afanasyev.   

Abstract

AIM: To study the influence of tumor removal on the serum level of IgG antibodies to tumor-associated Thomsen-Friedenreich (TF), Tn carbohydrate epitopes and xenogeneic alphaGal, and to elucidate on the change of the level during the follow-up as well as its association with the stage and morphology of the tumor and the values of blood parameters in gastrointestinal cancer.
METHODS: Sixty patients with gastric cancer and 34 patients with colorectal cancer in stages I-IV without distant metastases were subjected to follow-up. The level of antibodies in serum was determined by the enzyme-linked immunosorbent assay (ELISA) using synthetic polyacrylamide (PAA) glycoconjugates. Biochemical and haematological analyses were performed using automated equipment.
RESULTS: In gastrointestinal cancer, the TF antibody level was found to have elevated significantly after the removal of G3 tumors as compared with the preoperative level (u = 278.5, P < 0.05). After surgery, the TF and Tn antibody level was elevated in the majority of gastric cancer patients (sign test, 20 vs 8, P < 0.05, and 21 vs 8, P < 0.05, respectively). In gastrointestinal cancer, the elevated postoperative level of TF, Tn and alphaGal antibodies was noted in most patients with G3 tumors (sign test, 22 vs 5, P < 0.01; 19 vs 6, P < 0.05; 24 vs 8, P < 0.01, respectively), but the elevation was not significant in patients with G1 + G2 resected tumors. The postoperative follow-up showed that the percentage of patients with G3 resected tumors of the digestive tract, who had a mean level of anti-TF IgG above the cut-off value (1.53), was significantly higher than that of patients with G1 + G2 resected tumors (c2 = 3.89, all patients; c2 = 5.34, patients without regional lymph node metastases; P < 0.05). The percentage of patients with a tumor in stage I, whose mean anti-TF IgG level remained above the cut-off value (1.26), was significantly higher than that of patients with the cancer in stages III-IV (c2 = 4.71, gastric cancer; c2 = 4.11, gastrointestinal cancer; P < 0.05). The correlation was observed to exist between the level of anti-TF IgG and the count of lymphocytes (r = 0.517, P < 0.01), as well as between the level of anti-Tn IgG and that of serum CA 19-9 (r = 0.481, P < 0.05). No positive delayed-type hypersensitivity reaction in skin test challenges with TF-PAA in any of the fifteen patients, including those with a high level of anti-TF IgG, was observed.
CONCLUSION: The surgical operation raises the level of anti-carbohydrate IgG in most patients, especially in those with the G3 tumor of the gastrointestinal tract. The follow-up demonstrates that after surgery the low preoperative level of TF antibodies may be considerably increased in patients with the carcinoma in its early stage but remains low in its terminal stages. The stage- and morphology-dependent immunosuppression affects the TF-antibody response and may be one of the reasons for unresponsiveness to the immunization with TF-antigens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18666325      PMCID: PMC2731188          DOI: 10.3748/wjg.14.4352

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

1.  Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.

Authors:  W Reiter; P Stieber; C Reuter; D Nagel; U Lau-Werner; R Lamerz
Journal:  Anticancer Res       Date:  2000 Nov-Dec       Impact factor: 2.480

2.  Immunodeficiency in different histotypes of radically operable gastrointestinal cancers.

Authors:  F Romano; F Uggeri; S Crippa; G Di Stefano; M Scotti; A Scaini; R Caprotti; F Uggeri
Journal:  J Exp Clin Cancer Res       Date:  2004-06

3.  Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival.

Authors:  O Kurtenkov; K Klaamas; S Mensdorff-Pouilly; L Miljukhina; L Shljapnikova; V Chuzmarov
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

4.  Specificity of human anti-carbohydrate IgG antibodies as probed with polyacrylamide-based glycoconjugates.

Authors:  E P Smorodin; O A Kurtenkov; B L Sergeyev; G V Pazynina; N V Bovin
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

5.  Changes in serum levels of Forssman-like antibody in patients with gastric cancer.

Authors:  R Hirayama; K Hirokawa; Y Takagi; M Utsuyama; S Maejima; K Takemura; Y Mishima; T Makinodan
Journal:  Cancer       Date:  1989-04-15       Impact factor: 6.860

6.  Characterization of Thomsen-Friedenreich antibody subpopulations from normal human serum.

Authors:  M F Wolf; U Koerner; B Klumpp; K Schumacher
Journal:  Tumour Biol       Date:  1987

7.  Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease.

Authors:  Erika A Danna; Pratima Sinha; Mileka Gilbert; Virginia K Clements; Beth A Pulaski; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

8.  Forssman antibody levels in sera of cancer patients.

Authors:  T Mori; G Fujii; A Kawamura; T Yasuda; Y Naito; T Tsumita
Journal:  Immunol Commun       Date:  1982

9.  Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

Authors:  Susan F Slovin; Govindaswami Ragupathi; Cristina Musselli; Krystyna Olkiewicz; David Verbel; Scott D Kuduk; Jacob B Schwarz; Dalibor Sames; Samuel Danishefsky; Philip O Livingston; Howard I Scher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

10.  A unique natural human IgG antibody with anti-alpha-galactosyl specificity.

Authors:  U Galili; E A Rachmilewitz; A Peleg; I Flechner
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  9 in total

1.  Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients.

Authors:  Kristel Kodar; Jelena Izotova; Kersti Klaamas; Boris Sergeyev; Lilian Järvekülg; Oleg Kurtenkov
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

Review 2.  Bridging innate and adaptive antitumor immunity targeting glycans.

Authors:  Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal:  J Biomed Biotechnol       Date:  2010-06-15

3.  Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.

Authors:  Tatiana Pochechueva; Francis Jacob; Andre Fedier; Viola Heinzelmann-Schwarz
Journal:  Metabolites       Date:  2012-11-14

4.  The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients.

Authors:  Eugeniy Smorodin; Boris Sergeyev; Kersti Klaamas; Valentin Chuzmarov; Oleg Kurtenkov
Journal:  Int J Med Sci       Date:  2013-09-23       Impact factor: 3.738

5.  Serum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients.

Authors:  Shih-Yun Guu; Tsung-Hsien Lin; Su-Chieh Chang; Rei-Jing Wang; Ling-Yi Hung; Po-Jan Fang; Wei-Chien Tang; Peiwen Yu; Chuan-Fa Chang
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

Review 6.  Prospects and Challenges of the Study of Anti-Glycan Antibodies and Microbiota for the Monitoring of Gastrointestinal Cancer.

Authors:  Eugeniy P Smorodin
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

Review 7.  Tumor-Associated Glycans and Immune Surveillance.

Authors:  Behjatolah Monzavi-Karbassi; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Vaccines (Basel)       Date:  2013-06-17

8.  Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer.

Authors:  Oleg Kurtenkov; Kersti Klaamas
Journal:  Dis Markers       Date:  2015-11-18       Impact factor: 3.434

Review 9.  Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.

Authors:  Oleg Kurtenkov
Journal:  Biomed Res Int       Date:  2020-03-23       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.